Tumor Marker Concentration Predicts Treatment Failure in Testicular Cancer
Author Information
Author(s): R de Wit, R Sylvester, C Tsitsa, PHM de Mulder, DT Sleyfer, WW ten Bokkel Huinink, SB Kaye, AT van Oosterom, E Boven, K Vermeylen, G Stoter
Primary Institution: Rotterdam Cancer Institute
Hypothesis
Is the serum half-life of tumor markers a reliable predictor of treatment failure in patients with disseminated non-seminomatous testicular cancer?
Conclusion
Initial serum concentrations of HCG and AFP are significant predictors of treatment failure, while their half-lives are not.
Supporting Evidence
- 42% of patients had normal HCG and 37% had normal AFP at the start of chemotherapy.
- Initial marker concentrations of HCG and/or AFP ≥ 1000 IU 1-1 were highly significant prognosticators for treatment failure.
- Half-lives of HCG and AFP did not accurately predict treatment failure.
Takeaway
Doctors can tell if chemotherapy will work better by looking at certain blood markers at the start, rather than how long those markers stay in the body.
Methodology
The study analyzed serum half-lives of HCG and AFP during chemotherapy and their relationship with treatment failure in 669 patients.
Limitations
Half-lives could not be calculated for patients whose markers normalized before day 22.
Participant Demographics
Patients with disseminated non-seminomatous testicular cancer treated with cisplatin combination chemotherapy.
Statistical Information
P-Value
p=0.001 for HCG; p<0.001 for AFP
Statistical Significance
p<0.001
Want to read the original?
Access the complete publication on the publisher's website